TB-500 is a synthetic peptide based on a fragment of a natural protein called thymosin beta-4 (Tβ4), a 43-amino-acid molecule found in nearly all human and animal cells that is involved in cell movement and tissue repair.12
The region most associated with TB-500 is Tβ4's "actin-binding" sequence, Leu-Lys-Lys-Thr-Glu-Thr-Gln (LKKTETQ), shown schematically above.2
One honest complication: the label "TB-500" is used loosely in the marketplace. Some products contain this short actin-binding fragment; others contain the full Tβ4 sequence. That inconsistency is itself part of why regulators treat these products cautiously. TB-500 is not an FDA-approved drug.
In plain English: TB-500 is a lab-made piece of a natural body protein that shows up wherever you get hurt. People talk about it for recovery.
What the research shows - and what it doesn't
Most published work on Tβ4 and TB-500 is preclinical. Animal studies describe faster closure of skin wounds, effects in corneal and cardiac injury models, and roles in muscle repair.12
Early human research on the parent protein thymosin beta-4 has been explored in areas such as diabetic foot ulcers and dry-eye disease, but large randomized human trials remain limited.1
What the published record does not include is a body of large, well-controlled human trials showing that TB-500 itself is safe and effective for any condition. Promising signals in animals are not the same as proven benefit in people.12
Why TB-500 keeps coming up in recovery circles
The excitement traces back to its parent, thymosin β-4 - a molecule the body deploys wherever tissue is damaged. In animal models the fragment speeds wound closure, supports muscle and even heart-tissue repair, and improves flexibility, which is why it's a fixture in recovery conversations.12
The honest asterisks are real: the confirming human trials haven't been run, and
commercial
"TB-500" varies in what's actually in the vial.
How to read peptide research. Animal-study and cell-study findings describe what happened in a controlled experiment. They are a starting point for investigation, not evidence that a compound works - or is safe - in humans. Peppies does not claim any peptide treats, cures, or prevents any condition.
In plain English: In animals it helped close wounds and repair muscle. But human proof is missing, and store-bought "TB-500" doesn't always contain the same thing.
Is TB-500 legal in 2026?
Here is the direct answer as of July 2026:
It is not an FDA-approved drug. There is no approved TB-500 product for any medical use.
It cannot be lawfully sold as a dietary supplement. The FDA treats unapproved injectable peptides marketed for human use as outside the lawful supplement framework.4
It currently has no cleared compounding pathway. TB-500 was placed in "Category 2" of the FDA's interim list of bulk drug substances for pharmacy compounding under section 503A - the category for substances that raise significant safety concerns - and although the FDA removed it (with eleven other peptides) from Category 2 in April 2026 and referred it to the advisory committee, removal did not add it to the approved ("Category
1") list.56
In plain terms, TB-500 sits in a regulatory gap: taken out of the explicitly-restricted bucket, but not placed into any approved one. Products sold as "research chemicals" or "not for human consumption" fall outside the approved framework.4
This section is educational and is not legal advice. Rules can vary and change; consult a qualified professional for your situation.
In plain English: It's not approved as a medicine or a supplement, and there's no legal made-to-order path for it yet.
The regulatory timeline
Sep 2023
FDA adds this and other peptides to Category 2 of the interim 503A bulks list, citing safety concerns such as limited human data.3
Apr 2026
FDA removes 12 peptides - including this one - from Category 2 and sets an advisory committee review.56
Jul 23, 2026 (Day 1)
The Pharmacy Compounding Advisory Committee meets to review seven peptides. The FDA-evaluated use here is wound healing.3
After the meeting
The committee's vote is advisory only. FDA then decides whether to begin formal rulemaking to add (or not add) this peptide to the 503A list. In its briefing materials, FDA staff proposed not adding the peptides under review.37
Where the public comes in
The July 23-24 advisory meeting has its own public docket (FDA-2025-N-6895), but that docket closes July 22, 2026, and the committee's vote is only a recommendation. The decision that actually determines access comes later, if and when the FDA opens a formal rulemaking. That is the public comment window that carries legal weight - and it is the moment Peppies is tracking.
Want to know the moment you can comment?
Join the list and we'll send a clear, step-by-step heads-up when the official public comment window opens - so your voice counts when it matters.
TB-500 is not an FDA-approved drug and has no cleared compounding pathway. It was in Category 2 of the interim 503A list, then removed in April 2026 and referred to the July 2026 advisory committee. Removal did not place it on the approved list.356
Is TB-500 the same as thymosin beta-4?
Not exactly. TB-500 is based on a fragment of the natural 43-amino-acid protein thymosin beta-4, and commercial 'TB-500' labeling is inconsistent - some products use the short actin-binding fragment, others the full protein.12
What was TB-500 evaluated for at the July 2026 meeting?
The FDA-evaluated use listed for TB-500 is wound healing.3
Where to learn more
Want to dig into the primary science yourself? These are neutral, authoritative starting points - no sales pitch, just the record:
We link only to independent, authoritative sources - U.S. and international (NIH, FDA, Europe PMC/EMBL-EBI, and the EU/U.S. trial registries) - never to sellers.
References
"Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review." Applied Sciences (MDPI), 2026. mdpi.com/2076-3417/16/12/6202www.mdpi.com
U.S. Food and Drug Administration. "July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee." Agenda, evaluated uses, briefing materials, and docket FDA-2025-N-6895. fda.gov - PCAC July 2026 meetingwww.fda.gov
U.S. Food and Drug Administration - consumer information on unapproved peptide products and dietary-ingredient status. fda.gov - compounding Q&Awww.fda.gov
Federal Register. "Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments - Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List." April 16, 2026. federalregister.govwww.federalregister.gov
Hyman, Phelps & McNamara. "FDA's Pep(tide) Rally: What Compounders and Industry Need to Know." FDA Law Blog, April 2026 (12 peptides removed from Category 2). thefdalawblog.comwww.thefdalawblog.com
